Triptorelin
Also known as · Decapeptyl · Trelstar · GnRH agonist
Overview
A potent GnRH agonist used clinically for prostate cancer, endometriosis, and precocious puberty. An initial gonadotropin surge is followed by sustained axis suppression.
Research profile · for clinicians
Based on research: extensively documented in oncology and reproductive endocrinology. The biphasic flare-then-suppression profile is the defining pharmacology to understand.
Mechanism of action
Continuous high-affinity GnRH receptor occupancy first triggers a surge in LH/FSH, then downregulates and desensitises the receptor, producing profound suppression of gonadal steroid output.
Research record
- [01]Established depot therapy for advanced prostate cancer and endometriosis.
- [02]Single-dose protocols studied for restarting the HPG axis after suppression.
Selected references
Triptorelin in the treatment of prostate cancer
Drugs, 2010
Research deep dive
Every cited study, explained
Plain-language walkthroughs of each reference, with direct PubMed links and dosing-literature context.